Evidence map›Paper›PMID 40429890›Full record

ReviewInternational journal of molecular sciences2025

The Role of microRNAs in Inflammatory Bowel Disease.

Aneta Sokal-Dembowska, Sara Jarmakiewicz-Czaja, Kacper Helma, Rafał Filip

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aneta Sokal-DembowskaFaculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.ORCID 0000-0003-4727-8766
Sara Jarmakiewicz-CzajaFaculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.ORCID 0000-0001-6896-4744
Kacper HelmaFaculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland.ORCID 0000-0003-1845-9621
Rafał FilipDepartment of Internal Medicine, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-959 Rzeszow, Poland.ORCID 0000-0002-5954-151X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulation of microRNAs (miRNAs) has been implicated in the development of inflammatory bowel disease (IBD). Specific miRNAs are differentially expressed in patients with IBD compared to healthy individuals. Regulation of their expression can modulate the inflammatory response, the composition of the intestinal microbiota, and intestinal barrier function. miRNAs can regulate the immune and inflammatory response via multiple mechanisms, from Th1/Th17 regulation and ferroptosis to modulation of NLRP3 (NOD-like receptor family, pyrin domain-containing 3) and control of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. The use of miRNAs as biomarkers and therapeutic targets may help monitor IBD treatment and support the development of new, more individualized therapies that minimize common side effects.

Indexed as

Inflammatory Bowel DiseasesMicroRNAsAnimalsBiomarkersGastrointestinal MicrobiomeGene Expression RegulationHumansNLR Family, Pyrin Domain-Containing 3 ProteinBiomarkersMicroRNAsNLR Family, Pyrin Domain-Containing 3 ProteinCrohn’s diseaseinflammatory bowel diseasemicroRNAulcerative colitis

Identifiers

PMID40429890
PMCPMC12111732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.